精神神经因素在银屑病发病中的作用

doi:10.3760/cma.j.issn.0412-4030.2019.03.013

Abstract

Abstract: 【Abstract】 Considerable evidence has indicated that psychological factors, such as anxiety, nervousness and mental stress, can induce or exacerbate psoriasis and affect therapeutic effects to a certain degree, suggesting that psychological factors may play an important role in the occurrence of psoriasis. Current researches on neuropsychiatry-related pathogenesis of psoriasis mainly include two aspects: on the one hand, acting as stressors, psychological factors can activate the following two neuroendocrine systems, including hypothalamic-pituitary-adrenocortical axis and sympathetic-adrenal medullary system; on the other hand, neuropeptides and nerve growth factors induce in vivo neurogenic inflammation. Neuropsychiatric factors may participate in the occurrence of psoriasis through the above pathways.

Key words: Psoriasis, Anxiety, Stress, psychological, Neuropeptides, Nerve growth factors, Hypothalamic?pituitary?adrenocortical axis, Sympathetic?adrenal medullary system

Gao Yimeng, Jin Hongzhong. The role of neuropsychiatric factors in the occurrence of psoriasis[J]. Chinese Journal of Dermatology, 2019, 52(3): 204-207.doi:10.3760/cma.j.issn.0412-4030.2019.03.013

References ［42］

［1］	Manolache L, Petrescu⁃Seceleanu D, Benea V. Life events involvement in psoriasis onset/recurrence［J］. Int J Dermatol, 2010,49（6）:636⁃641. doi: 10.1111/j.1365⁃4632.2009.04367.x.
［2］	Malhotra SK, Mehta V. Role of stressful life events in induction or exacerbation of psoriasis and chronic urticaria［J］. Indian J Dermatol Venereol Leprol, 2008,74（6）:594⁃599.
［3］	Verhoeven EW, Kraaimaat FW, de Jong EM, et al. Individual differences in the effect of daily stressors on psoriasis: a prospective study［J］. Br J Dermatol, 2009,161（2）:295⁃299. doi: 10.1111/j.1365⁃2133.2009.09194.x.
［4］	Chen K, Wang G, Jin H, et al. Clinic characteristics of psoriasis in China: a nationwide survey in over 12 000 patients［J］. Oncotarget, 2017,8（28）:46381⁃46389. doi: 10.18632/oncotarget. 18453.
［5］	Yan D, Afifi L, Jeon C, et al. A cross⁃sectional study of psoriasis triggers among different ethno⁃racial groups［J］. J Am Acad Dermatol, 2017,77（4）:756⁃758.e1. doi: 10.1016/j.jaad.2017.04. 1109.
［6］	Kouris A, Platsidaki E, Kouskoukis C, et al. Psychological parameters of psoriasis［J］. Psychiatriki, 2017,28（1）:54⁃59. doi: 10.22365/jpsych.2017.281.54.
［7］	Fortune DG, Richards HL, Kirby B, et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy［J］. Arch Dermatol, 2003,139（6）:752⁃756. doi: 10.1001/archderm.139.6.752.
［8］	Snast I, Reiter O, Atzmony L, et al. Psychological stress and psoriasis: a systematic review and meta⁃analysis［J］. Br J Dermatol, 2018,178（5）:1044⁃1055. doi: 10.1111/bjd.16116.
［9］	Hunter HJ, Griffiths CE, Kleyn CE. Does psychosocial stress play a role in the exacerbation of psoriasis?［J］. Br J Dermatol, 2013,169（5）:965⁃974. doi: 10.1111/bjd.12478.
［10］	Alexopoulos A, Chrousos GP. Stress⁃related skin disorders［J］. Rev Endocr Metab Disord, 2016,17（3）:295⁃304. doi: 10.1007/s11154⁃016⁃9367⁃y.
［11］	Chen Y, Lyga J. Brain⁃skin connection: stress, inflammation and skin aging［J］. Inflamm Allergy Drug Targets, 2014,13（3）:177⁃190.
［12］	Bilgiç Ö, Bilgiç A, Sivrikaya A, et al. Association between endocrinological, immunological and psychosocial variables in psoriasis patients［J］. G Ital Dermatol Venereol, 2016,151（6）:603⁃609.
［13］	Evers AW, Verhoeven EW, Kraaimaat FW, et al. How stress gets under the skin: cortisol and stress reactivity in psoriasis［J］. Br J Dermatol, 2010,163（5）:986⁃991. doi: 10.1111/j.1365⁃2133.2010. 09984.x.
［14］	Brunoni AR, Santos IS, Sabbag C, et al. Psoriasis severity and hypothalamic⁃pituitary⁃adrenal axis function: results from the CALIPSO study［J］. Braz J Med Biol Res, 2014,47（12）:1102⁃1106. doi:10.1590/1414⁃431X20143762
［15］	Karanikas E, Harsoulis F, Giouzepas I, et al. Stimulation of the hypothalamic⁃pituitary⁃adrenal axis with corticotropin releasing hormone in patients with psoriasis［J］. Hormones （Athens）, 2007,6（4）:314⁃320.
［16］	Theoharides TC, Stewart JM, Taracanova A, et al. Neuroendo⁃crinology of the skin［J］. Rev Endocr Metab Disord, 2016,17（3）:287⁃294. doi: 10.1007/s11154⁃016⁃9369⁃9.
［17］	Slominski AT, Zmijewski MA, Zbytek B, et al. Key role of CRF in the skin stress response system［J］. Endocr Rev, 2013,34（6）:827⁃884. doi: 10.1210/er.2012⁃1092.
［18］	Zhou CL, Yu XJ, Cai DX, et al. Inhibiting interleukin⁃18 production through the mitogen⁃activated protein kinase pathway, a potential role of corticotropin⁃releasing hormone in chronic plaque psoriasis［J］. Inflammation, 2015,38（3）:1003⁃1011. doi: 10.1007/s10753⁃014⁃0064⁃2.
［19］	Zhou C, Yu X, Cai D, et al. Role of corticotropin⁃releasing hormone and receptor in the pathogenesis of psoriasis［J］. Med Hypotheses, 2009,73（4）:513⁃515. doi: 10.1016/j.mehy.2009.02. 051.
［20］	Cemil BC, Canpolat F, Yilmazer D, et al. The association of PASI scores with CRH⁃R1 in patients with psoriasis［J］. Arch Dermatol Res, 2012,304（2）:127⁃132. doi: 10.1007/s00403⁃012⁃1218⁃4.
［21］	Vasiadi M, Therianou A, Sideri K, et al. Increased serum CRH levels with decreased skin CRHR⁃1 gene in psoriasis and atopic dermatitis［J］. J Allergy Clin Immunol, 2012,129（5）:1410⁃1413. doi: 10.1016/j.jaci.2012.01.041.
［22］	Loite U, Kingo K, Reimann E, et al. Gene analysis of the corticotrophin⁃releasing hormone⁃proopiomelanocortin system in psoriasis skin biopsies［J］. Acta Derm Venereol, 2013,93（4）:400⁃405. doi: 10.2340/00015555⁃1524.
［23］	Lee JH, Cho DH, Park HJ. IL⁃18 and cutaneous inflammatory diseases［J］. Int J Mol Sci, 2015,16（12）:29357⁃29369. doi: 10.3390/ijms161226172.
［24］	Vandevyver S, Dejager L, Tuckermann J, et al. New insights into the anti⁃inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid⁃receptor⁃mediated transacti⁃vation［J］. Endocrinology, 2013,154（3）:993⁃1007. doi: 10.1210/en.2012⁃2045.
［25］	Man XY, Li W, Chen JQ, et al. Impaired nuclear translocation of glucocorticoid receptors: novel findings from psoriatic epidermal keratinocytes［J］. Cell Mol Life Sci, 2013,70（12）:2205⁃2220. doi: 10.1007/s00018⁃012⁃1255⁃3.
［26］	Hannen R, Udeh⁃Momoh C, Upton J, et al. Dysfunctional skin⁃derived glucocorticoid synthesis is a pathogenic mechanism of psoriasis［J］. J Invest Dermatol, 2017,137（8）:1630⁃1637. doi: 10.1016/j.jid.2017.02.984.
［27］	Madva EN, Granstein RD. Nerve⁃derived transmitters including peptides influence cutaneous immunology［J］. Brain Behav Immun, 2013,34:1⁃10. doi: 10.1016/j.bbi.2013.03.006.
［28］	Schallreuter KU, Wood JM, Lemke R, et al. Production of catecholamines in the human epidermis［J］. Biochem Biophys Res Commun, 1992,189（1）:72⁃78.
［29］	Stohl LL, Zang JB, Ding W, et al. Norepinephrine and adenosine⁃5′⁃triphosphate synergize in inducing IL⁃6 production by human dermal microvascular endothelial cells［J］. Cytokine, 2013,64（2）:605⁃612. doi: 10.1016/j.cyto.2013.08.005.
［30］	Zhou J, Yan J, Liang H, et al. Epinephrine enhances the response of macrophages under LPS stimulation［J］. Biomed Res Int, 2014,2014:254686. doi: 10.1155/2014/254686.
［31］	Gupta K, Harvima IT. Mast cell⁃neural interactions contribute to pain and itch［J］. Immunol Rev, 2018,282（1）:168⁃187. doi: 10.1111/imr.12622.
［32］	Zhu TH, Nakamura M, Farahnik B, et al. The role of the nervous system in the pathophysiology of psoriasis: a review of cases of psoriasis remission or improvement following denervation injury［J］. Am J Clin Dermatol, 2016,17（3）:257⁃263. doi: 10.1007/s40257⁃016⁃0183⁃7.
［33］	Keçici AS, Göktay F, Tutkavul K, et al. Unilateral improvement of nail psoriasis with denervation injury［J］. Clin Exp Dermatol,2018,43（3）:339⁃341. doi: 10.1111/ced.13337.
［34］	Szepietowski JC, Reich A. Pruritus in psoriasis: an update［J］. Eur J Pain, 2016,20（1）:41⁃46. doi: 10.1002/ejp.768.
［35］	Kubanov AA, Katunina OR, Chikin VV. Expression of neuropeptides, neurotrophins, and neurotransmitters in the skin of patients with atopic dermatitis and psoriasis［J］. Bull Exp Biol Med, 2015,159（3）:318⁃322. doi: 10.1007/s10517⁃015⁃2951⁃4.
［36］	Lotti T, D′Erme AM, Hercogová J. The role of neuropeptides in the control of regional immunity［J］. Clin Dermatol, 2014,32（5）:633⁃645. doi: 10.1016/j.clindermatol.2014.04.011.
［37］	Ostrowski SM, Belkadi A, Loyd CM, et al. Cutaneous denervation of psoriasiform mouse skin improves acanthosis and inflam⁃mation in a sensory neuropeptide⁃dependent manner［J］. J Invest Dermatol, 2011,131（7）:1530⁃1538. doi: 10.1038/jid.2011.60.
［38］	Ding W, Stohl LL, Xu L, et al. Calcitonin gene⁃related peptide⁃exposed endothelial cells bias antigen presentation to CD4+ T cells toward a Th17 response［J］. J Immunol, 2016,196（5）:2181⁃2194. doi: 10.4049/jimmunol.1500303.
［39］	Ding W, Manni M, Stohl LL, et al. Pituitary adenylate cyclase⁃activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells［J］. Eur J Immunol, 2012,42（4）:901⁃911. doi: 10.1002/eji.201141958.
［40］	Zhang J, Ma WY. Nerve growth factor regulates the of vascular endothelial growth factor in human HaCaT keratinocytes via PI3K/mTOR pathway［J］. Genet Mol Res, 2014,13（4）:9324⁃9335. doi: 10.4238/2014.January.24.14.
［41］	Brunoni AR, Lotufo PA, Sabbag C, et al. Decreased brain⁃derived neurotrophic factor plasma levels in psoriasis patients［J］. Braz J Med Biol Res, 2015,48（8）:711⁃714. doi: 10.1590/1414⁃431X2015 4574.
［42］	Truzzi F, Marconi A, Atzei P, et al. p75 neurotrophin receptor mediates apoptosis in transit⁃amplifying cells and its overexp⁃ression restores cell death in psoriatic keratinocytes［J］. Cell Death Differ, 2011,18（6）:948⁃958. doi: 10.1038/cdd.2010.162.

[1]	Liu Xiaoyang, Zhao Yan, Cai Lin, Zhang Jianzhong. Atopic dermatitis-like lesions appearing after interleukin-17 antagonist therapy in 4 cases of psoriasis: case analysis and literature review [J]. Chinese Journal of Dermatology, 2023, 56(9): 845-848.
[2]	Fu Dandan, Li Jialin, Fu Xiuyu, Zhang Xinyu, Hu Hua, Song Xiangfeng, Tian Zhongwei. S100A10 protein expression in psoriatic lesions and its effect on psoriasis-like skin inflammation in mouse models [J]. Chinese Journal of Dermatology, 2023, 56(9): 839-844.
[3]	Chen Xiaomin, Zhang Jingzhan, Ding Yuan, Kang Xiaojing. Metformin in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(8): 799-802.
[4]	Jiang Xiaoyan, Gao Min, Zhang Xiaoyan, Liu Ningyuan. Interleukin-17 and interleukin-23 inhibitors in the treatment of pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(7): 689-692.
[5]	Shan Ying, Chang Xiaotong, Zuo Yagang. Epitope spreading in autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2023, 56(7): 702-705.
[6]	Tang Zhiming, Jing Mengqing, Lu Lu, Shan Xiao, Zhang Cuixia, Zhang Xiaoyu, Meng Sa. Effect of Xidi Liangxue recipe on the proliferation and apoptosis of HaCaT cells through the lncRNA NEAT1/miR-485-5p/STAT3 regulatory network [J]. Chinese Journal of Dermatology, 2023, 56(7): 642-650.
[7]	Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China （2023 edition） [J]. Chinese Journal of Dermatology, 2023, 56(7): 573-625.
[8]	China Dermatologist Association, Chinese Society of Dermatology, Xijing Hospital, Air Force Medical University, Chinese Dietary Guideline for Psoriasis Patients Task Force. Dietary guideline for patients with psoriasis in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 389-401.
[9]	Jin Liping, Zhu Wu, Lu Yan, Liu Panpan, Tan Minjia, Wang Ying, Yang Jing, Xu Licong, Hu Kun, Kuang Yehong. Dietary intervention for the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(4): 357-360.
[10]	Lian Panpan, Liu Jun, Su Zhonglan, Wang Hongwei. Effect of peroxisome proliferator-activated receptor γ on skin physiological and pathological processes [J]. Chinese Journal of Dermatology, 2023, 56(4): 365-368.
[11]	Wang Shiqi, Wang Aiping, Li Hang, Li Ruoyu. Comparison of dermoscopic features of toenail psoriasis and fingernail psoriasis [J]. Chinese Journal of Dermatology, 2023, 0(3): 20220544-e20220544.
[12]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.
[13]	Zhou Jian, Yu Chen, Wang Gang. Clinical efficacy and safety of secukinumab in the treatment of 13 cases of refractory localized pustular psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 247-251.
[14]	Hu Kun, Yang Jing, Wang Qiaolin, Chen Junchen, Zhang Mi, Zhu Wu, Zhang Bin, Dou Guanshen, Wendong Chen, Kuang Yehong. Real-world short-term treatment effects of Ixekizumab in Chinese patients with psoriasis: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(3): 210-215.
[15]	He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278.

The role of neuropsychiatric factors in the occurrence of psoriasis

PDF

Knowledge

Abstract

Cite this article

share this article

References ［42］

Related Articles 15

Metrics

Comments

Recommended 10